P. Cassier

A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma.

Richard D. Baird, Kinjal Shah, Bristi Basu et al. · Journal of Clinical Oncology · 2011 · 39 citations

Medicine, Oncology, Pharmacology +17

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers

Christophe Le Tourneau, J.P. Delord, P. Cassier et al. · Annals of Oncology · 2019 · 21 citations · Full text

Medicine, Immunology, Oncology +17

A phase I, open-label, multi-center, dose escalation study of oral NVP-CGM097, a p53/HDM2-protein-protein interaction inhibitor, in adult patients with selected advanced solid tumors

Sebastian Bauer, George D. Demetri, Sébastien Jeay et al. · Annals of Oncology · 2016 · 18 citations · Full text

Medicine, Oncology, Pharmacology +14

54P Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)

John Bridgewater, Funda Meric‐Bernstam, Antoine Hollebecque et al. · Annals of Oncology · 2020 · 17 citations

Medicine, Oncology, Pharmacology +16

Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors

David M. Hyman, Manash Chatterjee, Marlies H.G. Langenberg et al. · European Journal of Cancer · 2016 · 15 citations

Medicine, Oncology, Cancer Genetics +9